Skip to main content
. Author manuscript; available in PMC: 2019 Mar 16.
Published in final edited form as: Mucosal Immunol. 2018 Aug 16;11(6):1716–1726. doi: 10.1038/s41385-018-0067-7

Figure 3. Infection rates and plasma viral loads of passively breast milk mAb-infused, SHIV-challenged infant RMs.

Figure 3.

A) Proportion of viremic RMs with 6/8 control mAb-treated RMs (red), 3/6 DH378 mAb-treated RMs (blue; Fisher’s exact test; FDR-corrected p=0.58), and 2/6 tri-mAb-treated RMs (green; Fisher’s exact test; FDR-corrected p=0.55) demonstrating viremia as defined by a detectable plasma viral RNA load at any tested time point. B) Plasma viral RNA loads in mAb treated, orally SHIV challenged infant RMs. * indicates significantly higher 2 week post infection plasma viral RNA loads in DH378 mAb-treated RMs compared to CH65-treated RMs (Wilcoxon test; FDR-corrected p=0.05). Animals with HLA type A001 or B17 are annotated appropriately in the legend.